Helse Nord-Trondelag HF
- Address
- Kirkegata 2, 7600 Levanger, Norway
Helse Nord-Trondelag HF - Endocrine Research Center
Helse Nord-Trondelag HF is a clinical research center specializing in endocrine disorders, with particular expertise in adrenal insufficiency management. The center conducts comparative effectiveness studies examining different glucocorticoid replacement therapies and their impact on patient outcomes.
- Primary adrenal insufficiency treatment optimization
- Health-related quality of life assessments in endocrine disorders
- Comparative studies of glucocorticoid replacement therapies
The center's CORTAD study represents a comprehensive approach to evaluating treatment modalities for primary adrenal insufficiency (PAI), focusing on longitudinal assessment of patient well-being through health-related quality of life (HRQoL) measurements. This research aims to provide evidence-based guidance for optimizing glucocorticoid replacement therapy in patients with adrenal insufficiency.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 56 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Oslo University Hospital HF3active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Oslo University Hospital HF4trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Helse Nord-Trondelag HF
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter Non-Inferiority Trial Comparing Rituximab and Ocrelizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis Aged 18-60 Years | Helse Bergen HF | Phase III | Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 56 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 2 | Unknown | 2018-07-31 | 2021-04-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.